SV-BR-1-GM, A Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses An Immune Signature And Directly Activates CD4+ T Lymphocytes

Lacher, M. D., Bauer, G., Fury, B., Graeve, S., Fledderman, E. L., Petrie, T. D., Coleal-Bergum, D. P., Hackett, T., Perotti, N. H., Kong, Y. Y., Kwok, W. W., Wagner, J. P., Wiseman, C. L., Williams, W. V. SV-BR-1-GM, A Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses An Immune Signature And Directly Activates CD4+…

Read More

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine Conjugated Antibody–Drug Conjugate Targeting 5T4

Harper, Lloyd, Dimasi, Toader, Marwood, Lewis, Bannister, Jovanovic, Fleming, d’Hooge, Mao, Marrero, Korade, Strout, Xu, Chen, Wetzel, Breen, van Vlerken-Ysla, Jalla, Rebelatto, Zhong, Hurt, Hinrichs, Huang, Howard, Tice, Hollingsworth, Herbst, Kamal. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine Conjugated Antibody–Drug Conjugate Targeting 5T4. Mol Cancer Ther; 16(8) August 2017. DOI: 10.1158/1535-7163.MCT-16-0825

Read More